AssetMark Inc’s Phio Pharmaceuticals PHIO Stock Holding History

AssetMark Inc’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113	Hold	110	–	–	﹤0.01%	3468
2026 Q1	$134	Hold	110	–	–	﹤0.01%	3362
2025 Q4	$116	Hold	110	–	–	﹤0.01%	3297
2025 Q3	$273	Hold	110	–	–	﹤0.01%	3016
2025 Q2	$259	Hold	110	–	–	﹤0.01%	2843
2025 Q1	$143	Buy	+110	New	+$203	﹤0.01%	2548

Other funds holding PHIO

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AssetMark Inc's PHIO Position: Q2 2026 in Review

AssetMark Inc held its Phio Pharmaceuticals (PHIO) position steady in Q2 2026 at 110 shares worth $113. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

AssetMark Inc first reported a position in PHIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $273 in Q3 2025. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

AssetMark Inc held 110 shares of Phio Pharmaceuticals worth $113 as of Q2 2026.
AssetMark Inc left its Phio Pharmaceuticals share count unchanged in Q2 2026.
Phio Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3468 holding.
AssetMark Inc first reported a position in Phio Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
AssetMark Inc's Phio Pharmaceuticals position peaked at $273 in Q3 2025.
24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.